Kolon Life Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kolon Life Science makes pharmaceutical ingredients and finished medicines, and also operates a supply-chain services business that handles logistics and distribution for other pharmaceutical companies.
Its products and services reach licensed drug manufacturers and healthcare providers. Listed on KOSDAQ, Korea's tech and small-cap exchange, the company runs three distinct divisions, pharmaceuticals, supply-chain services, and a biotechnology unit, with supply-chain services now accounting for the largest share of overall revenue.
Summary is AI-generated and may contain errors · figures from DART filings
Kolon Life Science in five facts
What does Kolon Life Science do?
Kolon Life Science makes pharmaceutical ingredients and finished medicines, and also operates a supply-chain services business that handles logistics and distribution for other pharmaceutical companies.
Where is Kolon Life Science listed and in which sector?
Kolon Life Science (Korean name: 코오롱생명과학) trades under KRX code 102940 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Kolon Life Science?
Its market capitalisation was US$133.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kolon Life Science's latest annual revenue and operating profit?
For fiscal year 2025, Kolon Life Science reported revenue of US$157.7M, operating profit of US$13.3M and net income of US$18.8M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 29.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Half-year report (2026.06)Aug 31
- [quarterly, individual company] Large business group status disclosureAug 31
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Kolon Life Science updated its previously filed consolidated results for FY2025: revenue of US$143M (+29.5% year on year), operating profit of US$12M (from a loss a year earlier) and net income of US$17.1M (from a loss a year earlier).
Earnings · Mar 5 · 2 versions - [Amended] Material event report (convertible bonds)
Kolon Life Science updated the terms of convertible bonds to raise US$20.5M, about 15.8% of its market value.
Capital raise · Mar 5